06 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Merck, also known as MSD outside the US and Canada, received US FDA approval for Liptruzet (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
Liptruzet treats two sources of cholesterol by inhibiting both the absorption of cholesterol in the digestive tract through ezetimibe and the production of cholesterol in the liver through atorvastatin. No incremental benefit of Liptruzet on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established.
Dr Peter H Jones, associate professor of medicine, Baylor College of Medicine, US, said that, "A significant percentage of patients are unable to lower their LDL cholesterol to recommended levels despite treatment."
Dr Jones said, "Along with a healthy diet, Liptruzet (ezetimibe and atorvastatin) is an effective new lipid-lowering treatment option that may help address this unmet need as the complementary actions of its components can provide significant additional LDL lowering beyond atorvastatin therapy alone."